Currently, there are 224.29M common shares owned by the public and among those 193.80M shares have been available to trade.
The company’s stock has a 5-day price change of 3.02% and 28.98% over the past three months. INCY shares are trading 7.96% year to date (YTD), with the 12-month market performance up to 7.45% higher. It has a 12-month low price of $50.27 and touched a high of $70.36 over the same period. INCY has an average intraday trading volume of 3.62 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.85%, 10.86%, and 16.31% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Incyte Corp. (NASDAQ: INCY) shares accounts for 108.79% of the company’s 224.29M shares outstanding.
It has a market capitalization of $13.36B and a beta (3y monthly) value of 0.73. The stock’s trailing 12-month PE ratio is 20.57, while the earnings-per-share (ttm) stands at $3.29. The company has a PEG of 0.66 and a Quick Ratio of 3.43 with the debt-to-equity ratio at 0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.64% over the week and 2.86% over the month.
Earnings per share for the fiscal year are expected to decrease by -25.32%, and 105.11% over the next financial year. EPS should shrink at an annualized rate of 31.00% over the next five years, compared to 38.99% over the past 5-year period.
Looking at the support for the INCY, a number of firms have released research notes about the stock. BMO Capital Markets stated their Underperform rating for the stock in a research note on July 02, 2024, with the firm’s price target at $52-$48. Deutsche Bank coverage for the Incyte Corp. (INCY) stock in a research note released on May 23, 2024 offered a Hold rating with a price target of $55. Cantor Fitzgerald was of a view on April 23, 2024 that the stock is Neutral, while Jefferies gave the stock Buy rating on February 23, 2024, issuing a price target of $81. JMP Securities on their part issued Mkt Perform rating on February 14, 2024.
